Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.

MLA

He, Ying, et al. “Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.” Frontiers in Immunology, vol. 12, July 2021, p. 641206. EBSCOhost, https://doi.org/10.3389/fimmu.2021.641206.

APA

He, Y., Hung, S. W., Liang, B., Zhang, R., Gao, Y., Chu, C. Y., Zhang, T., Xu, H., Chung, J. P. W., & Wang, C. C. (2021). Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis. Frontiers in Immunology, 12, 641206. https://doi.org/10.3389/fimmu.2021.641206

Chicago

He, Ying, Sze Wan Hung, Bo Liang, Ruizhe Zhang, Yating Gao, Ching Yan Chu, Tao Zhang, Hui Xu, Jacqueline Pui Wah Chung, and Chi Chiu Wang. 2021. “Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.” Frontiers in Immunology 12 (July): 641206. doi:10.3389/fimmu.2021.641206.